News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Daxor Corporation (DXR) Announces Basic Blood Volume Research Study on Renal Dialysis Patients


11/8/2012 9:37:39 AM

NEW YORK, NY--(Marketwire - November 08, 2012) -

Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, today announced the presentation of a study on Radioisotope Blood Volume Measurement in Hemodialysis Patients. A study headed by Dr. David Goldfarb was presented at the recent American Society of Nephrology (ASN) annual meeting held in San Diego. Dr. Goldfarb performed this work with Drs. Sonika Puri, Jun-Ki Park, Aditya Matoo and Frank Modersitzki.

The study performed at the New York Harbor VA Healthcare Center was the first study ever performed where complete blood volume measurements were performed on renal dialysis patients before they underwent renal dialysis and shortly after dialysis was completed. Renal dialysis is usually performed three times a week on patients who have kidney failure. The renal dialysis process involves filtering a patient's blood obtained from a large vein, and returning the blood to another vein over a period of two to four hours. Without dialysis such patients would soon die from an accumulation of toxic waste products. Renal dialysis patients are sometimes able to obtain a donated kidney which enables them to live without dialysis. Only a small percentage of kidney failure patients, however, are able to obtain a donated kidney.

A dialysis procedure removes toxic waste products as well as excess fluid from the body of these patients who produce no urine because they have total kidney failure. 65% of renal dialysis patients die within 5 years of beginning dialysis. 25% of patients have a so-called crash episode at least once a year in which blood pressure drops to extremely low levels. This study by Dr. Goldfarb demonstrated that patients have significant variability in response to dialysis treatment as to whether the fluid removed comes from their blood volume or from their extra cellular water.

At the present time physicians administering dialysis treatment do not have an accurate way of evaluating the source of the fluid being removed from the patient. The use of a blood volume measurement in conjunction with a simple
crit-line, which measures hematocrit concentration, can enable a physician to determine, during dialysis, the source of the fluid being removed from the patient and potentially avoid a severe drop in blood pressure.

Dr. Goldfarb is the medical director of hemodialysis at the New York Harbor VA Healthcare Center, and Professor of Medicine and Physiology at NYU School of Medicine. Dr. Goldfarb is willing to discuss his findings with medical personnel. He can be reached at the New York Harbor VA. He prefers to be initially contacted via e-mail at david.goldfarb@va.gov. The study can be found on Daxor's website at www.Daxor.com. The link to this study is
http://www.daxor.com/pdfs/ASN2012_Park_Radioisotope.pdf.

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.


Daxor Contact Information:
Richard Dunn
Director of Operations
212-330-8502
Email Contact

Diane Meegan
Investor Relations
212-330-8512
Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES